多发性骨髓瘤的诊断及免疫治疗研究进展

Progress in the diagnosis and immunotherapy of multiple myeloma

多发性骨髓瘤(MM)发病机制研究的深入及新药的广泛应用,对MM的检测手段及疗效评价提出了进一步的要求。2018年美国血液学会(ASH)年会中推荐使用低剂量CT而不是普通X线片作为初诊MM患者的骨骼是否累及的筛查;治疗方面,单抗在MM治疗中的地位得到进一步巩固,嵌合抗原受体T细胞(CAR-T)治疗全面发展。

The research on the pathogenesis of multiple myeloma (MM) and the wide application of new drugs have put forward further requirements for the detection methods and efficacy evaluation of MM.In the 2018 American Society of Hematology (ASH) Annual Meeting,low-dose CT was recommended instead of plain X-ray as a screening method for the skeletal involvement in newly diagnosed MM patients.In terms of treatment,the status of monoclonal antibodies in MM treatment was further consolidated,and the chimeric antigen receptor T cell (CAR-T) immunotherapy was fully developed.